Is rapamycin approved for longevity?

No. It is FDA-approved for organ-transplant rejection prevention and for LAM. Longevity use is off-label and not endorsed by clinical guidelines.

Why weekly dosing instead of daily?

Daily dosing produces continuous immunosuppression and full side-effect burden. Weekly dosing aims to capture mTORC1 inhibition while sparing mTORC2 and reducing infection / glucose / lipid effects. Whether this dosing schedule preserves the mouse-lifespan benefit in humans is an open question.

Can I take rapamycin and metformin together?

Some longevity-clinic protocols combine them. There is no human RCT data on the combination, and they may have additive side effects (glucose, mucosal). Discuss with a physician.

What about rapalogs like everolimus or temsirolimus?

Everolimus has been studied in MANNICK's elderly-immune trials. Temsirolimus is an oncology drug at much higher doses. The off-label longevity use uses sirolimus, primarily for cost and dosing convenience.

Intervention

Rapamycin

Last updated Mon Jun 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time)· 5 min read· Evidence: rct

RCT evidence— Mouse lifespan reproducible across labs; PEARL human RCT published

What it is

Rapamycin (sirolimus) is a macrolide produced by Streptomyces hygroscopicus, first isolated from a soil sample on Easter Island (Rapa Nui) in 1972. It binds FKBP12 and the resulting complex inhibits mTORC1, the master regulator of cellular growth and nutrient signalling. It is FDA-approved as an immunosuppressant for organ transplant (sirolimus) and as Rapamune for lymphangioleiomyomatosis.

Why it’s of interest for longevity

Rapamycin (and its analog everolimus / RAD001) is the most reproducibly life-extending pharmaceutical in mammals. The NIA’s Interventions Testing Program showed median-lifespan extension in genetically heterogeneous mice across three independent sites at multiple ages, including late-life dosing initiated at the mouse equivalent of human age ~65. The effect is robust to genetic background, larger in females, and dose-dependent.

Mechanism

mTORC1 inhibition produces a coordinated cellular shift:

Reduced protein synthesis (4E-BP1, S6K1 dephosphorylation).
Raised autophagy (macroautophagy and mitophagy).
Improved proteostasis (HSF1 activation; reduced misfolded-protein load).
Reduced ribosomal biogenesis.
Improved immune-cell function in older adults via reduced T-cell exhaustion (the PI3K/mTOR axis intersection).

This recapitulates much of the conserved dietary restriction programme, acting downstream of nutrient sensing.

Dosing comparison

Rapamycin dosing across indications
Indication	Typical dose	Trough level target	Notes
Solid-organ transplant	2–10 mg/day	5–15 ng/mL	Continuous immunosuppression; side-effect-heavy
LAM (Rapamune label)	2 mg/day	5–15 ng/mL	FDA-approved indication
MANNICK 2014 (elderly immune)	0.5 mg/day or 5 mg weekly (RAD001 equivalents)	Low / intermittent	Improved vaccine response in elderly
PEARL trial (healthspan)	5 or 10 mg weekly	Not targeted	Body-composition, function endpoints
Longevity-clinic off-label	5–8 mg once weekly	Not measured	Variable; not standardised

Human evidence

Approved transplant use: large safety database at higher continuous doses; side-effect profile well-characterised.
MANNICK 2014 (Novartis, with everolimus): low-dose intermittent mTOR inhibition improved influenza-vaccine response in older adults.
PEARL trial: decentralised RCT of weekly rapamycin in healthy older adults; modest functional and body-composition improvements without serious safety signals at the doses tested.
Off-label longevity-clinic use is widespread but lacks long-term RCT outcomes data.

Who is considering it

The 'who should consider' question

There is no clinical guideline supporting off-label rapamycin for longevity. Adults who pursue it under physician supervision typically:

Are 40+ with multiple cardiometabolic risk factors.
Have addressed lifestyle foundations (exercise, sleep, lipids, BP).
Accept uncertain long-term benefit and known short-term side effects.
Can afford regular monitoring (CBC, CMP, lipids, glucose).
Are NOT trying to conceive (animal data suggest fertility effects).
Are NOT immunocompromised or in active infection.
Understand it’s an investigational use.

If any of these criteria don’t apply, the risk-benefit calculation shifts unfavourably.

Monitoring schedule (if used off-label)

Baseline + 6-week: CBC, CMP, lipid panel, HbA1c, urinalysis.
Every 6 months thereafter: same panel.
Annually: full physical, dermatology check (mouth ulcers, acneiform rash), cardiovascular review.
Watch for: persistent mouth ulcers, lower-extremity oedema, shortness of breath (pneumonitis), poor wound healing.

Safety

Even at low intermittent doses, expect:

Stomatitis (mouth ulcers) — the most common signal of dose-limiting toxicity.
Impaired wound healing — pause around surgery.
Glucose intolerance / hyperglycaemia.
Dyslipidaemia (LDL and triglycerides rise).
Lower-extremity oedema.
Increased infection risk.
Interstitial pneumonitis (rare but serious).
Female fertility issues.

Drug interactions via CYP3A4 are major: grapefruit juice, clarithromycin, ketoconazole, ritonavir, calcium-channel blockers, and many others can substantially raise rapamycin levels.

Controversies and uncertainty

Optimal dosing schedule: weekly intermittent vs. more frequent remains unsettled.
Sex differences: ITP showed larger lifespan effect in females; human translation unclear.
Late-life initiation: works in mice; uncertain how late is "too late" in humans.
Combination protocols: rapamycin + metformin? + senolytics? — not studied in humans.

FAQ

Is rapamycin approved for longevity?: No. It is FDA-approved for organ-transplant rejection prevention and for LAM. Longevity use is off-label and not endorsed by clinical guidelines.
Why weekly dosing instead of daily?: Daily dosing produces continuous immunosuppression and full side-effect burden. Weekly dosing aims to capture mTORC1 inhibition while sparing mTORC2 and reducing infection / glucose / lipid effects. Whether this dosing schedule preserves the mouse-lifespan benefit in humans is an open question.
Can I take rapamycin and metformin together?: Some longevity-clinic protocols combine them. There is no human RCT data on the combination, and they may have additive side effects (glucose, mucosal). Discuss with a physician.
What about rapalogs like everolimus or temsirolimus?: Everolimus has been studied in MANNICK's elderly-immune trials. Temsirolimus is an oncology drug at much higher doses. The off-label longevity use uses sirolimus, primarily for cost and dosing convenience.

References

Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392–395 (2009).
Kaeberlein, M. & Galvan, V. Rapamycin and Alzheimer's disease. Sci. Transl. Med. 11, eaar4289 (2019).
Mannick, J. B. et al. mTOR inhibition improves immune function in the elderly. Sci. Transl. Med. 6, 268ra179 (2014).